No abstract available
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Bevacizumab
-
Blindness / congenital*
-
Blindness / diagnosis
-
Blindness / drug therapy
-
Blindness / genetics
-
DNA Mutational Analysis
-
Eye Proteins / genetics
-
Female
-
Fluorescein Angiography
-
Genetic Diseases, X-Linked
-
Humans
-
Infant
-
Infant, Newborn
-
Intravitreal Injections
-
Laser Coagulation
-
Low Density Lipoprotein Receptor-Related Protein-5 / genetics
-
Male
-
Mutation
-
Nerve Tissue Proteins / genetics
-
Nervous System Diseases / diagnosis
-
Nervous System Diseases / drug therapy*
-
Nervous System Diseases / genetics
-
Pedigree
-
Pregnancy
-
Premature Birth*
-
Retinal Degeneration
-
Retinal Hemorrhage / diagnosis
-
Retinal Hemorrhage / surgery
-
Retinal Neovascularization / diagnosis
-
Retinal Neovascularization / drug therapy*
-
Retinal Neovascularization / genetics
-
Siblings
-
Spasms, Infantile / diagnosis
-
Spasms, Infantile / drug therapy*
-
Spasms, Infantile / genetics
-
Ultrasonography, Prenatal
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Eye Proteins
-
LRP5 protein, human
-
Low Density Lipoprotein Receptor-Related Protein-5
-
NDP protein, human
-
Nerve Tissue Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab